Affimed GmbH   Report issue

For profit Phase 1 Phase 2
Founded: Heidelberg Germany (2000)

Organization Overview

First Clinical Trial
2010
NCT01221571
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Affimed GmbH | Affimed Inc. | Amphivena Therapeutics | Amphivena Therapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hodgkin Disease (Phase 2)

Leukemia (Phase 1)

Leukemia, B-Cell (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Mycoses (Phase 2)

Mycosis Fungoides (Phase 2)

Myelodysplastic Syndromes (Phase 1)

Neoplasms (Phase 1)

Preleukemia (Phase 1)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 14
  • # of Trial APIs: 12